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Dendritic spines are the locus for excitatory synaptic transmission in the brain and
thus play a major role in neuronal plasticity. The ability to alter synaptic connections
includes volumetric changes in dendritic spines that are driven by scaffolds created by
the extracellular matrix (ECM). Here, we review the effects of the proteolytic activity
of ECM proteases in physiological and pathological structural plasticity. We use matrix
metalloproteinase-9 (MMP-9) as an example of an ECM modifier that has recently emerged
as a key molecule in regulating the morphology and dysmorphology of dendritic spines
that underlie synaptic plasticity and neurological disorders, respectively. We summarize
the influence of MMP-9 on the dynamic remodeling of the ECM via the cleavage
of extracellular substrates. We discuss its role in the formation, modification, and
maintenance of dendritic spines in learning and memory. Finally, we review research that
implicates MMP-9 in aberrant synaptic plasticity and spine dysmorphology in neurological
disorders, with a focus on morphological abnormalities of dendritic protrusions that are
associated with epilepsy.
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INTRODUCTION
Structural plasticity is an active field in neuroscience, with pivotal
implications for the understanding of many different levels of
learning and memory and a wide range of neurological and
cognitive disorders (Sala and Segal, 2014; Penzes et al., 2011).
Dendritic spines are plastic structures that undergo morphologi-
cal changes in response to stimuli that modulate neuronal activity.
Such remodeling underlies the formation and long-term storage
of information in the brain, and spine remodeling frequently
accompanies neurodegenerative diseases, i.e., ischemia (Brown
et al., 2008b) or spinal cord injury (Kim et al., 2006) lead to
a reduction in spine density and elongation of the remaining
spines; traumatic brain injury alters dendritic spines stability
(Campbell et al., 2012). The extracellular matrix (ECM) of the
brain mediates structural stability by creating a scaffold for den-
dritic spines (de Vivo et al., 2013). ECM components do not
constitute only a passive environment. Some ECM components
(e.g., matrix metalloproteinase-9 [MMP-9]) also actively partici-
pate in synaptic plasticity. Growing evidence indicates a particular
role for MMP-9 in the mediation of structural plasticity in the
brain.
In the present review, we discuss the concept of the tetra-
partite synapse, with a particular emphasis on ECM proteins, and
highlight both the beneficial and detrimental roles of MMP-9 in
pathological structural brain plasticity. We focus on epileptoge-
nesis as an example of a disease in which the role of MMP-9
in aberrant synaptic plasticity and permanent impairment is
particularly significant (Wilczynski et al., 2008).
TETRAPARTITE SYNAPSE
The first high-resolution observations of neurons by Ramón y
Cajal unveiled the existence of dendritic spines, small membra-
nous protrusions on the surface of dendrites (Ramón y Cajal,
1888, 1899). Ramón y Cajal theorized that they could be involved
in signal transmission within the brain (Ramón y Cajal, 1891,
1893), giving rise to the classical theory of a dipartite synapse
as a basic unit of neuronal information processing. The dipartite
synapse is formed by presynaptic and postsynaptic parts that are
found on presynaptic boutons and dendritic spines, respectively,
separated by the synaptic cleft. In the decades that followed,
research showed that this model was overly simplified, and addi-
tional players were added to the picture. The concept of a tripartite
synapse appeared, in which the astrocyte, once believed to be
an inert, “neuron-feeding” cell, actively participates in synaptic
transmission (Araque et al., 1999). Soon new components of the
synapse were discovered, giving rise to the tetrapartite or even
pentapartite concept of the synapse. In one conceptualization,
microglia (reviewed in De Leo et al., 2006) join pre- and post-
synaptic neurons and astrocytes to form the synapse. In another
conceptualization, the ECM is added as a key component of the
synapse (reviewed in Dityatev and Rusakov, 2011). The ECM
is a complex protein network that fills the extracellular space
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and is secreted by neurons, glia, and non-neuronal cells. It was
previously seen as an inert component of the synapse, a scaffold
that maintains synaptic integrity, with no effect on synaptic trans-
mission. The reality, however, turned out to be quite different.
Recent research has shown that the ECM actively regulates a
plethora of cellular functions, from the initial establishment of the
synapse to the regulation of synaptic transmission and synaptic
plasticity (reviewed in Dityatev et al., 2010). The ECM has begun
to be recognized as a critical factor that affects synapses by
enveloping them and forming a synaptic element. ECM compo-
nents with known roles in the regulation of synaptic transmission
include laminin, tenascins, thrombospondin, lectins, and MMPs,
to name a few (comprehensively reviewed in Dansie and Ethell,
2011). Among the numerous ECM components that have been
proposed to play roles in brain plasticity, MMP-9 has recently
emerged as a key molecule involved in long-term memory and
the underlying synaptic changes (Rivera et al., 2010; Huntley,
2012; Tsien, 2013). The focal point of synaptic changes within
the brain are dendritic spines that harbor synaptic contacts. Their
stability is correlated with their shape, in which mushroom-like
spines are generally more stable than thin, long spines. The size
of the spine head is well known to be correlated with the area of
the postsynaptic density (PSD; Harris and Stevens, 1989; Meyer
et al., 2014) and AMPA receptor number (Nusser et al., 1998;
Kharazia and Weinberg, 1999; Takumi et al., 1999; Szepesi et al.,
2014). Dendritic spine neck length on the other hand is correlated
with postsynaptic potential (Araya et al., 2006; Tønnesen et al.,
2014). Thus, dendritic spine morphology has been accepted to
determine the strength of synaptic connections. The structural
plasticity of dendritic spines is widely seen as the basis of the
primary functions of the central nervous system, including learn-
ing and memory. The influence of MMP-9 on dendritic spine
morphology makes it a perfect candidate molecule for synaptic
remodeling.
MATRIX METALLOPROTEINASE-9
MMP-9 is a 92 kDa protein that belongs to a family of zinc- and
calcium-dependent endopeptidases. Because of its ability to cleave
gelatin, it is classified as a gelatinase. It is encoded in the human
genome by a gene located on chromosome 20 (20q13.12). The
molecular biology of MMP-9 was summarized in an excellent,
exhaustive review by Vandooren et al. (2013).
MMP-9 has a complex domain structure, with a signal pep-
tide at the N-terminus, followed by a propeptide, a catalytic
domain with a zinc ion binding site, three fibronectin type II
inserts, a proline-rich and heavily O-glycosylated linker, and a
hemopexin domain located at the C-terminus of the protein
(Stute et al., 2003). The propeptide contains an evolutionarily
conserved PRCGVPDV domain that binds the zinc ion in the
catalytic domain and blocks the activity of the enzyme until it
is cleaved (Van Wart and Birkedal-Hansen, 1990; Becker et al.,
1995). The overlapping substrate specificity of MMPs (to date,
25 MMPs have been identified in humans) is attributable to a
zinc-binding motif, HExGHxxGxxH (where x signifies any amino
acid), within the catalytic domain, which is shared by all MMPs.
Tandemly repeated fibronectin type II inserts within the catalytic
domain are responsible for gelatin binding. The linker allows for
independent movement of the catalytic and hemopexin domains,
which influence enzyme conformation (Rosenblum et al., 2007)
and the substrate specificity of MMP-9. The hemopexin domain
is able to bind an endogenous MMP-9 inhibitor called tissue
inhibitor of matrix metalloproteinases-1 (TIMP-1) and several
MMP-9 substrates. It is also responsible for the membrane dock-
ing of MMP-9 (Bode et al., 1999) and formation of homo-
and heterodimers with neutrophil gelatinase-associated lipocalin
(NGAL; Kjeldsen et al., 1993; Cha et al., 2002).
MMP-9 is ubiquitously expressed throughout the body. Within
the resting brain, it is mostly synthesized by neurons but to some
extent also by glia in such structures as the hippocampus, cerebral
cortex, and cerebellum. It is extracellularly secreted, although
recent studies have also revealed its presence in the nucleus of
muscle cells (Yeghiazaryan et al., 2012), neurons (Yang et al.,
2010; Hill et al., 2012), human glial cells (Pirici et al., 2012),
and mitochondria of retinal capillary cells. MMP-9 may act as a
negative regulator of mitochondrial function and may be involved
in apoptosis (Kowluru et al., 2011).
The expression of MMP-9 is regulated on multiple levels:
(1) transcription (for a comprehensive review of the transcrip-
tional and epigenetic regulation of MMP-9 expression, including
regulation through non-coding RNAs, see Labrie and St-Pierre,
2013; several studies also indicate that reactive oxygen species
(ROS) activate MMP-9 expression through AP-1 transcription
factors; Hasebe et al., 2007; Hsieh et al., 2014); (2) posttranslation
(also involving non-proteolytic activation); (3) local translation
(Dziembowska et al., 2012); (4) sequestration on the cell mem-
brane (e.g., binding to cell adhesion molecules, such as hyaluro-
nian receptor CD44 (Bourguignon et al., 1998), integrins (Wang
et al., 2003), lipoprotein receptor-related protein-1 (LRP-1), and
megalin/LRP-2 (Van den Steen et al., 2006)); (5) internalization
(Hahn-Dantona et al., 2001); and (6) delayed activation that
involves cleavage of the propeptide and co-secretion with TIMP-
1, its endogenous inhibitor (Sbai et al., 2010). In the brain,
the primary transcriptional regulators of MMP-9 expression are
AP-1 and nuclear factor-κB (NF-κB). Yin Yang 1 (YY1) was
identified as a strong repressor of MMP-9 transcription in the
rat hippocampus in vivo and cultured neurons (Rylski et al.,
2008).
MMP-9 activation usually occurs through the cleavage of a
propeptide that disrupts its zinc ion binding properties. Cleavage
may also be performed by other MMPs and the tissue plasmino-
gen activator (tPA)-plasmin system (Bruno and Cuello, 2006).
However, non-proteolytic activation/inactivation is also possible
through posttranslational modification. The thiol modification
of methionine and cysteine residues within the catalytic domain
and nitration or oxidation of the propeptide cysteine that is
responsible for zinc ion binding are also able to activate MMPs
without propeptide removal. Finally, nitric oxide, a commonly
occurring secondary messenger in the brain, is able to regulate
the stability of MMP-9 mRNA (Akool et al., 2003).
MMP-9 and TIMP-1 are secreted by neurons in a Golgi-
dependent manner in 160–200 nm vesicles. The vesicles move
along microtubules and microfilaments. They are distributed in
the somatodendritic compartment and can be found in dendritic
spines (Sbai et al., 2008).
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MMP-9 regulates numerous cell activities through its involve-
ment in matrix remodeling and the liberation of macromolecules
(e.g., growth factors) that are embedded within the ECM. MMP-
9 is involved in various physiological functions, such as tissue
remodeling, cellular differentiation (Zimowska et al., 2013), cell-
cell contact and cell migration (Kim et al., 2012), the release of
cytokines and regulation of growth factor activity (Schonbeck
et al., 1998), survival and apoptosis (Kowluru et al., 2011), angio-
genesis, inflammation, and signaling (for a comprehensive review
of MMP-9 function, see Vandooren et al., 2013; Verslegers et al.,
2013). Aside from maintaining tissue homeostasis, MMP-9 plays a
role in a range of pathologies (comprehensively reviewed in Rivera
et al., 2010; Kaczmarek, 2013).
Polymorphisms that have been identified in the MMP-9 gene
promoter ([CA]n microsatellite at position -90 and SNP at -1562)
that affect the binding of nuclear proteins and thus the expression
levels of the protein were correlated with an increased incidence
of several pathologies in human populations (Ye, 2000). Addi-
tionally, a functional polymorphism that might affect the binding
of non-coding RNAs and thus mRNA transport and translation
was identified within the 3’ untranslated region of MMP-9 mRNA
(Yuan et al., 2013).
The monitoring of MMP-9 activity originally took advan-
tage of its gelatinolytic properties in the form of zymography,
in which MMP-9 cleaves an FITC-tagged gelatin (DQ-gelatin).
Under normal conditions, FITC fluorescence is almost completely
quenched unless DQ-gelatin is cleaved by MMP-9. In such a
case, fluorescence increases and can be readily monitored using
confocal microscopy. However, DQ-gelatin does not enable the
tracking of MMP-9 activity with high spatial and temporal reso-
lution because it is freely diffusive. Moreover, DQ-gelatin is also
cleaved by MMP-2, which generally has a much higher level of
expression than MMP-9. Therefore, assays that utilize DQ-gelatin,
with the exception of gel zymography, are highly nonspecific. In
recent years, a number of new MMP-9 activity biosensors have
been developed (Faust et al., 2008; Fudala et al., 2011; Akers
et al., 2012; Gustafson et al., 2013) in response to the perceived
shortcomings of classical zymographic approaches. The potential
of MMP-9 as a prognostic marker of cancer led to considerable
interest in developing diagnostic and analytical probes to detect
the proteolytic activity of MMP-9 in cancer (for a survey of
several MMP-9 activity probes used in cancer detection, see Roy
et al., 2011; for a review of MMP-9 detection methods in cancer,
see Scherer et al., 2008; for MMP-9 near-infrared fluorescence
probes in in vivo imaging, see Wallis de Vries et al., 2009; Kaijzel
et al., 2010; Akers et al., 2012; Lee et al., 2012). We recently
developed a genetically encoded fluorescence resonance energy
transfer (FRET)-based MMP-9 activity biosensor (Stawarski et al.,
2014) that is compatible with live cell imaging approaches and
can be used to study the effects of MMP-9 on structural plas-
ticity with very high spatiotemporal resolution. It is membrane-
anchored and utilizes the teal fluorescent protein (mTFP1) as
a donor of energy and two tandemly repeated Venus proteins
as energy donors to increase the resonant energy transfer level
(Figure 1). The biosensor was engineered for the highest possible
FRET efficiency and incorporates a synthetic MMP-9 cleavage site
within an α-helical region, giving the biosensor high sensitivity
to MMP-9 action and improved specificity. The biosensor can
be used to study the action of MMP-9 at the level of single
dendritic spines, providing an opportunity to unambiguously
correlate endogenous MMP-9 activity with the plastic changes of
dendritic spines. Furthermore, by combining the biosensor with
one of several recently described brain optical clearing techniques
(several optical clearing agents were recently reviewed in Zhu
et al., 2013; see also Chung et al. (2013) for CLARITY, Hama et al.
(2011) for Scale and Susaki et al. (2014) for CUBIC) bridging the
gap between studies of the global anatomical changes that occur
because of synaptic plasticity and locally regulated extremely
low-level proteolytic activity around single neurons might be
possible, thus providing insights into the basic mechanisms of
brain plasticity.
MMP-9 IN PHYSIOLOGICAL STRUCTURAL PLASTICITY
Research on MMP-9 was originally concentrated on its role in
the pathology of the central nervous system (e.g., post-injury
and post-stroke damage to brain tissue) due to its ECM-cleavage
properties. However, the first indication that MMP-9 may play a
role beyond the pathology of the brain came from research on
the kainate-induced epilepsy models in mice. Kainate-induced
seizures lead to massive cell death in CA regions of the hip-
pocampus, the limbic cortex, and the amygdala but a pronounced
plasticity in the dentate gyrus (DG; Zagulska-Szymczak et al.,
2001). Nedivi et al. (1993) demonstrated that TIMP-1 mRNA
(i.e., an endogenous inhibitor of MMPs, including MMP-9)
is upregulated following kainate-induced seizures. A follow-up
study (Szklarczyk et al., 2002) revealed that MMP-9 mRNA,
protein, and activity levels are also upregulated in the DG of
the hippocampus under the same experimental conditions. Fur-
thermore, Jaworski et al. (1999) observed that the expression
of TIMP-1 is coupled to neuronal excitation and spatially and
temporarily overlaps with c-Fos expression. Kuzniewska et al.
(2013) and Ganguly et al. (2013) also demonstrated that MMP-
9 expression depends on the c-Fos transcriptional regulation.
C-Fos role in brain plasticity was postulated already by Kacz-
marek et al. (2002). Nagy et al. (2006) and Bozdagi et al.
(2007) demonstrated that MMP-9 is a necessary component
of long-term potentiation (LTP; i.e., an experimental paradigm
that mimics certain aspects of physiological plasticity) both in
acute hippocampal slices and in vivo in urethane-anesthetized
rats. They discovered that MMP-9 is required in the late phase
of LTP in the CA1 field, and MMP-9 inhibition by whatever
means (e.g., inhibitors and antisense RNA) leads to a rapid
return of synaptic potentiation to baseline levels. Research on
MMP-9 knockout mice revealed diminished LTP that could be
rescued by exogenously applied recombinant MMP-9 (Nagy et al.,
2006). Meighan et al. (2006) demonstrated that spatial learning
leads to alterations in MMP-9 mRNA and protein levels. The
injection of either the broad-spectrum MMP inhibitor FN-439
or antisense RNA led to markedly diminished learning in the
Morris water maze. A similar effect was achieved with the N-
methyl-D-aspartate (NMDA) receptor antagonist MK801. Finally,
Meighan et al. (2006) demonstrated that the effect of MMPs on
learning is facilitated through changes of the actin cytoskeleton.
Recent studies also revealed that MMP-9 is required for cortical
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FIGURE 1 | MMP-9 activity detection mechanism of the biosensor. (A) In
an uncleaved state, the excitation energy is transferred from mTFP1 (depicted
in blue) to Venus (depicted in yellow), resulting in the fluorescence of the
yellow fluorescent protein. (B) Once MMP-9 cleaves the biosensor (sequence
recognized by MMP-9 is marked in red), the Venus proteins are released, the
FRET phenomenon disappears, and the fluorescence of mTFP1 increases. (C)
Time-lapse imaging of endogenous MMP-9 activity visualized with the
MMP-9 activity biosensor expressed in a primary rat hippocampal culture.
Colors indicate the value of Venus-to-mTFP1 fluorescence intensity ratio
(reds—high values of the ratio/uncleaved biosensor; blues—low values of the
ratio/cleaved biosensor; see the color bar below image insets). Stimulation
was performed with the chemical long-term potentiation (LTP) protocol (see
Stawarski et al., 2014). Biosensor pictures in the left and right of the diagram
indicate visually the state of the biosensor (uncleaved/cleaved).
plasticity evoked by sensory deprivation (e.g., whisker plucking
(Kaliszewska et al., 2012) and monocular deprivation (Spolidoro
et al., 2012)) and LTP in the mossy fiber-CA3 pathway (Wiera
et al., 2012, 2013). Physiological remodeling is also strongly
influenced by experience-dependent mechanisms that imply an
interaction between neural circuits and the external world. An
enriched environment has been shown to influence brain plastic-
ity by inducing MMP-9 activity (Foscarin et al., 2011; Cao et al.,
2014). More information on the role of MMP-9 in physiological
plasticity can be found in recently published reviews (Rivera et al.,
2010; Wlodarczyk et al., 2011).
Matrix metalloproteinases are functionally involved in the
regulation of synaptic plasticity (Nagy et al., 2006; Bozdagi et al.,
2007; Okulski et al., 2007; Rivera et al., 2010; Huntley, 2012;
Szepesi et al., 2013) and formation and maintenance of den-
dritic spines (Wang et al., 2008; Bilousova et al., 2009; Michaluk
et al., 2011). Although details of MMP-9 action on dendritic
spines are not fully elucidated, the research performed so far
allowed to construct a model of MMP-9 activity around dendritic
spines, which is presented in Figure 2. The model postulates that
MMP-9 is released from dendritic spines following a stimulus.
MMP-9 activity, possibly mediated through β1 integrin signal-
ing causes the elongation of dendritic spines and increases the
mobility of NMDA receptors. The time window in which MMP-
9 is active is brief, as it is almost immediately inactivated by
its endogenous inhibitor TIMP-1. MMP-9 inhibition allows the
dendritic spines to mature, incorporate AMPA receptors and
form active synapses. The model presented above is supported by
numerous observations, which are briefly summarized in the next
paragraph.
The presence of MMP-9-coding mRNA, protein, and enzy-
matic activity at the level of dendritic spines was confirmed by
recent studies (Konopacki et al., 2007; Wilczynski et al., 2008;
Gawlak et al., 2009; Dziembowska et al., 2012). The activity-
dependent local translation of MMP-9 mRNA and protein release
was recently demonstrated by Dziembowska et al. (2012), sup-
porting the hypothesis that locally secreted MMP-9 and other
dendritically synthesized proteins are involved in the structural
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FIGURE 2 | MMP-9 involvement in morphological changes of dendritic
spines in LTP and possible role in epileptogenesis-related spine
pathology. (A) Dendritic spines extend as small protrusions from dendritic
shaft. (B1) MMP-9 level is elevated upon stimulus which leads to spine
elongation and (C1) maturation. (B2) Fast (within minutes) activation of MMP-9
by injury or seizures may induce spine loss. (C2) Continuous increase of
MMP-9 (secondary to seizures, within days) may cause regrowth of dendritic
spines and contribute to long-term circuitry remodeling underlying seizures.
and functional plasticity of activated synapses. MMP-9 also
increases the lateral mobility of NMDARs (Michaluk et al., 2009).
Michaluk et al. (2011) also demonstrated that elongation and
spine thinning are regulated by integrin β1 signaling and are
accompanied by changes in the decay time of miniature synaptic
currents. The blockade of integrin β1 signaling with an integrin
β1 antibody abolished both the MMP-9-dependent increase in
NMDAR mobility and its ability to affect spine morphology. The
ICAM-5 ectodomain produced by MMP-9 cleavage stimulates an
increase in AMPA mini excitatory postsynaptic current (mEPSC)
frequency and leads to recruitment of the AMPAR GluA1 subunit
to the membrane (Lonskaya et al., 2013).
The activity of MMP-9 that was locally released in response to
stimuli was also recently reported to modulate the morphology
of dendritic spines (Wang et al., 2008; Bilousova et al., 2009).
Admittedly, there is some confusion on how exactly MMP-9
affects the spine morphology, with different groups reporting
markedly different effects, with some groups observing spine mat-
uration following MMP-9 activity, while others report dendritic
spine elongation. Wang observed that MMP-9 was required in
spine enlargement associated with LTP in acute hippocampal
slices. That observation indicates that MMP-9 may drive the
establishment of persistent modification of both synapse struc-
ture and function (Wang et al., 2008). Intracellular adhesion
molecule-5 (ICAM-5) cleavage by MMP-9 causes the elongation
of dendritic filopodia in dissociated neuronal cultures (Tian
et al., 2007) and influences AMPAR-dependent glutamatergic
transmission. Our research indicates that the enzymatic activ-
ity of MMP-9 is able to cause an elongation and thinning of
dendritic spines on hippocampal neurons in three experimental
models: transgenic rats that overexpress auto-activating MMP-
9, dissociated hippocampal cultures, and organotypic cultures
(Michaluk et al., 2011). Bilousova observed that the incubation
of dissociated neuronal cultures with recombinant MMP-9 led
to the transformation of mushroom-shaped dendritic spines
into filopodia-like protrusions (Bilousova et al., 2009). Minocy-
cline, a drug whose pleiotropic effects include the inhibition
of MMP-9 activity, reverses filopodia transformation toward
mature spines in an animal model of fragile X syndrome (Fmr1
knockout mice). Apparently conflicting effects of MMP-9 on
spine structure and dynamics can be explained by different
research protocols, including enzyme concentration, treatment
duration, and age and developmental stage of the neurons. The
research discussed above also differs in the manner by which
MMP-9 was applied (i.e., bath application vs. local application),
the duration of MMP-9 activity influenced by the inhibitory
effect of TIMP-1 (an endogenous MMP-9 inhibitor), and the
maturity of neurons. Wang et al. (2008) observed that MMP-9
Frontiers in Neuroanatomy www.frontiersin.org July 2014 | Volume 8 | Article 68 | 5
Stawarski et al. MMP-9 related dendritic spine reshaping
promotes the maturation of dendritic spines, whereas Tian et al.
(2007) and Michaluk et al. (2011) reported something markedly
different (i.e., MMP-9 or MMP-9-released products stimulated
spine elongation). Wang et al. (2008) performed their studies
using acute slices from postnatal day 14 (PD14) to PD21 rats,
whereas Michaluk et al. (2011) chose an organotypic culture
model from PD7 rats. Furthermore, Wang et al. (2008) applied
MMP-9 locally with a stimulating electrode, which more closely
resembles physiological conditions, in contrast to the study by
Michaluk et al. (2011), who used bath application, which is closer
to pathological conditions. MMP-9 activity is thus believed to
be strictly regulated, local, and transient, and the inhibition of
MMP-9 may be the final step in spine maturation, in which a
filopodium-like protrusion matures into a mushroom-like den-
dritic spine (Tian et al., 2007; Bilousova et al., 2009). Studying
the effect of TIMP-1 sequestration on spine morphology might
be advantageous.
Spine head protrusions (SHPs) are small filopodia-like pro-
cesses that extend from the dendritic spine head. They represent
a new type of postsynaptic structural remodeling that follows
neuronal activity. We recently reported the role of MMP-9 in the
formation of SHPs (Szepesi et al., 2013). Chemically induced LTP
(cLTP) leads to the upregulation of MMP-9 activity in dissociated
hippocampal cultures and appears to control SHP formation.
The growth of SHPs is abolished by inhibiting MMP activity or
influencing microtubule dynamics. Recombinant auto-activating
MMP-9 promotes the formation of SHPs in organotypic hip-
pocampal slices. Spines with SHPs were also shown to recruit
new postsynaptic AMPA receptors following cLTP, and AMPAR
recruitment was MMP-dependent.
Research indicates that the effect of MMP-9 on spine mor-
phology may be mediated not by a general disruption of ECM
structure (Michaluk et al., 2009) but rather by the tightly regu-
lated cleavage of specific ECM proteins that would then trigger
the intracellular integrin signaling pathway (Wang et al., 2008;
Michaluk et al., 2011). The modifications of spine morphology
appear to involve MMP-9 cleavage of the following proteins:
β-dystroglycan, ICAM-5, integrins (MMP-9 is known to cleave
integrin β2; Vaisar et al. (2009), and β4 (Pal-Ghosh et al., 2011).
Indirect evidence also suggests that MMP-9 may drive the cleavage
of integrin β1 (Kim et al., 2009), neuroligin-1, and ephrin (Nagy
et al., 2006; Michaluk et al., 2007, 2009; Tian et al., 2007; Conant
et al., 2010; Peixoto et al., 2012). The MMP-9-driven cleavage of
ICAM-5, a negative regulator of spine maturation, was observed
following neuronal stimulation and led to spine maturation (Tian
et al., 2007; Conant et al., 2010). Peixoto et al. (2012) observed
that neuroligin-1 cleavage by MMP-9 at the postsynaptic site
of glutamatergic synapses resulted in a destabilized presynaptic
site and modification of synaptic transmission. The Ephrin/Eph
receptor complex, cleaved by MMP-9 following hippocampal LTP,
is involved in learning and memory (Klein, 2004; Murai and
Pasquale, 2004). Therefore, MMP-9 is clearly an important player
in the dynamic remodeling of dendritic spines, and its affinity for
numerous proteins supports the concept of a tetrapartite synapse
(Dityatev and Rusakov, 2011).
Matrix metalloproteinases also process various non-ECM pro-
teins, such as growth factor precursors, cell-surface receptors,
and adhesion molecules (Nagase and Woessner, 1999; Ethell and
Ethell, 2007; Michaluk and Kaczmarek, 2007). Several MMP-9
substrates were identified only in vitro (e.g., the ECM and the
basement membrane molecules brevican, laminin and aggrecan;
Nakamura et al., 2000; Overall, 2002; Morrison et al., 2009) and
not confirmed in vivo. β-dystroglycan (β-DG) was confirmed to
be cleaved by MMP-9 in vivo in response to enhanced neuronal
activity (Michaluk et al., 2007). β-DG is a transmembrane protein
that serves as a cell-surface anchor for α-dystroglycan, which
binds to the extracellular domains of β-DG and laminin, agrin,
and perlecan (Ervasti and Campbell, 1993; Gee et al., 1993; Bowe
et al., 1994; Campanelli et al., 1996; Peng et al., 1998; Henry et al.,
2001) in non-neuronal cells and neurexins in the central nervous
system (Sugita et al., 2001). Thus, MMP-9 activity may uncouple
the cytoskeleton from the ECM. Other cell-surface receptors that
were confirmed to be MMP-9 substrates include the interleukin-2
(IL-2) receptor α chain (CD25; Sheu et al., 2001; De Paiva et al.,
2009), ephrin B (Lin et al., 2008), and NG2 proteoglycan in the
spinal cord (Larsen et al., 2003).
Bajor et al. (2012) isolated two synaptic proteins that are
cleaved in vivo by MMP-9: synaptic cell adhesion molecule-2
(synCAM-2) and collapsin response mediator protein-2 (CRMP-
2). CRMP-2 is involved in axon guidance, neurite outgrowth,
and the regulation of neuronal differentiation (Inagaki et al.,
2001; Fukata et al., 2002; Yoshimura et al., 2005). It was sug-
gested to play a role in numerous neurological diseases, such
as Alzheimer’s disease, epilepsy, and ischemia (Gu and Ihara,
2000; Czech et al., 2004; Uchida and Goshima, 2005). SynCAM-2
(also known as Necl-3, IgSF4D, and Cadm-2) is a Ca2+-binding
immunoglobulin-like transmembrane protein that is expressed
by neurons in the developing and adult brain. It is localized to
the synaptic cleft and contributes to synaptic organization and
function (Fogel et al., 2007).
Growth factors and signaling molecules that were confirmed to
be processed by MMP-9 in vivo include IL-8 (Van den Steen et al.,
2000), pro brain-derived neurotrophic factor (BDNF; Hwang
et al., 2005; Mizoguchi et al., 2011a), pro tumor necrosis factor
α (TNF-α; Roghani et al., 1999), and pro transforming growth
factor β (TGF-β; Yu and Stamenkovic, 2000). The ability of MMP-
9 to cleave β-amyloid peptide is particularly interesting because
an increase in MMP-9 expression was observed in Alzheimer’s
disease patients by several research groups (Backstrom et al., 1996;
Yan et al., 2006; Mizoguchi et al., 2011a; Filippov and Dityatev,
2012).
MMP-9 IN ABERRANT STRUCTURAL PLASTICITY
Accumulating evidence suggests that MMP-9 may also play a
relatively direct role in other forms of learning and memory,
including those associated with addiction. Many drugs and alco-
hol induce neuroplastic changes in pathways that subserve emo-
tion and cognition. Elevated MMP-9 activity has been implicated
in the synaptic remodeling that is important for the reactiva-
tion of cocaine memory in rats (Brown et al., 2008a). In mice,
methamphetamine treatment resulted in the rapid upregulation
of MMP-9 (Liu et al., 2008; Conant et al., 2011). MMP-9 has
also been implicated in the plastic changes induced by alcohol
addiction (Samochowiec et al., 2010). Importantly, both drug and
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chronic alcohol exposure cause structural alterations of dendrites
and their spines (Zhou et al., 2007; Shen et al., 2009).
The importance of MMP-9 in shaping dendritic spine archi-
tecture in disease is further supported by autism and mental
retardation studies. Fragile X syndrome is a form of inherited
intellectual disability (Hagerman et al., 2005; Bagni et al., 2012).
Patients with fragile X syndrome have aberrant dendritic spine
morphology (Rudelli et al., 1985). Long and thin immature
dendritic spines are also observed in Fmr1 knockout mice, a
model of fragile X syndrome (Comery et al., 1997). MMP-9
has been shown to be highly increased in the fragile X syn-
drome mouse model (Bilousova et al., 2009). The reduction
of MMP-9 levels induced by minocycline promoted dendritic
spine maturation and improved general behavioral performance.
High MMP-9 activity levels are also lowered by minocycline in
fragile X syndrome patients (Dziembowska et al., 2013). Notably,
minocycline has been tested in clinical trials to treat fragile X
syndrome and shown to provide significant functional benefits
(Paribello et al., 2010; Utari et al., 2010; Leigh et al., 2013).
Matrix metalloproteinases have also been implicated in other
forms of autism (Abdallah and Miche1, 2013). MMP-9 levels are
elevated in patients with Autism Spectrum Disorder (Abdallah
et al., 2012). MMP-9 levels are also increased in patients with
schizophrenia (Rybakowski et al., 2013), and dendritic spine
alterations have been identified in multiple brain regions in
schizophrenia (Glausier and Lewis, 2013).
Aberrant structural plasticity is a major phenomenon associ-
ated with epilepsy (Scharfman, 2002). Epilepsy is a brain disorder
characterized by an enduring predisposition to the generation
of epileptic seizures, understood as sudden excessive neuronal
discharges. In many cases, epilepsy develops as a result of brain
damage caused by traumatic brain injury, stroke, or infection
(Banerjee and Hauser, 2008). The primary insult is associated
with an increased incidence of secondary injuries that can develop
within hours to days or even weeks. Secondary brain injury
is thought to be responsible for the development of many of
the aforementioned sustained neurological deficits (Bolkvadze
and Pitkanen, 2012; Rezaei et al., 2012; Mollayeva et al., 2013).
Patients with epilepsy frequently suffer from memory impair-
ment, behavioral problems, and psychiatric disorders (Dodrill,
2002; Helmstaedter, 2002; Williams, 2003; Elger et al., 2004;
Berg, 2011). Dendritic spines receive a majority of excitatory
synaptic inputs. Transmission and dendritic spine shape and
function are strictly related, and such structural changes likely
constitute hallmarks of pathology and the observed cognitive
deficits.
Indeed, abnormalities in dendritic spines have been commonly
associated with human epilepsy and animal models of epilepsy
(Swann et al., 2000; Wong, 2005). A prominent decrease in den-
dritic spine density has been observed in pyramidal neurons in the
hippocampus and neocortex and dentate granule cells in patients
with temporal lobe epilepsy (Multani et al., 1994; Jiang et al., 1998;
Blümcke et al., 1999; Freiman et al., 2011; Kitaura et al., 2011).
Similar aberrations have been observed in animal models of
epilepsy (Jiang et al., 1998; González-Burgos et al., 2004; Ampuero
et al., 2007). Notably, other alterations, such as an increase in
dendritic spine number or size, have also been reported (Represa
et al., 1993; Suzuki et al., 1997; Isokawa, 2000). These common
features of both human and animal studies indicate that den-
dritic spine abnormalities represent an important factor in the
pathological mechanisms of posttraumatic epilepsy, but it is still
unclear whether they are more related to the cause or consequence
of seizures (Wong and Guo, 2013). Furthermore, dendritic spine
pathology may be both the cause and consequence of seizures.
Alterations in dendritic spine structure or function can affect
the processing of synaptic inputs. Seizures are implicated in
excessive neuronal excitability, and these changes may constitute a
compensatory response in the form of a homeostatic mechanism.
However, the loss of excitatory input eventually affects inhibitory
networks, which in turn may cause increased excitability and an
inclination toward seizures.
An important issue are the mechanisms that are involved in
dendritic spine pathology in epilepsy. The ECM constitutes a
natural milieu for dendritic spines, and ECM remodeling may
potentially influence epileptogenesis on many different levels,
predominantly related to structural reorganization. Extracellular
structural networks stabilize cellular and synaptic components.
When pathology occurs, however, these stable components break
down, which may lead to abnormal structural reorganization
(i.e., dendritic spine loss or axonal sprouting) that promotes cir-
cuitry reorganization and epileptogenesis. Seizures lead to striking
remodeling of the ECM, which may be essentially engaged in dif-
ferent aspects of epileptogenesis (Dityatev, 2010; Lukasiuk et al.,
2011). Metalloproteinases, enzymes that modulate the ECM, grow
to be important players in these processes. Evidence for a role
of MMP-9 in physiological and aberrant synaptic plasticity and
posttraumatic epileptogenesis is especially strong, in contrast to
other MMPs (Lukasiuk et al., 2011).
Some evidence also comes from human studies. The critical
role of MMP-9 in pathology following trauma is supported by
clinical studies, in which elevated levels of MMP-9 were detected
in cerebrospinal fluid from patients with severe traumatic brain
injury (Grossetete et al., 2009). Prolonged seizures are also related
to high serum MMP-9 levels in patients (Suenaga et al., 2008).
MMP-9 is also upregulated in the cortex in patients with focal
cortical dysplasia, a disorder associated with intractable cortical
epilepsy (Konopka et al., 2013). Notably, the prominent upregu-
lation of MMP-9 was observed mainly at postsynaptic sites (i.e.,
at dendritic spines).
The involvement of the MMP-9 proteolytic system has been
widely studied in animal models of epilepsy. After traumatic
brain injury, the activation of MMP-9 in lesioned cortex occurred
within 1 day following trauma and remained elevated for 7 days
after the initial insult (Hadass et al., 2013). Moreover, treatment
with an MMP-9 inhibitor effectively attenuated MMP-9 activity,
reduced brain lesion volume, and prevented neuronal loss and
dendritic degeneration (Hadass et al., 2013). Similarly, after brain
trauma, MMP-9 protein levels are increased compared with the
contralateral cortex, with a peak 24 h following injury and eleva-
tions that persist for up to 1 week. Moreover, MMP-9 knockout
mice have smaller traumatic brain lesion volumes (Wang et al.,
2000).
MMP-9 is also induced during status epilepticus after treat-
ment with kainate (Zhang et al., 2000; Szklarczyk et al., 2002;
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FIGURE 3 | MMP-9 immunoreactivity (IR) in the Dentate Gyrus (DG) of
control animal and 1–7 days following intra-amygdalar kainic acid (KA)
administration. (A) Immediately after KA administration MMP-9 IR is low
and distributed equally across DG layers. (B–D) MMP-9 IR increases after
KA injection. (C–D) Note increased IR of MMP-9 predominantly in molecular
layer (ML). (D) Seven days post KA administration neuronal MMP-9
reservoir is enriched with astrocytic pool. Confocal images from brain tissue
labeled with nuclear marker (DAPI—white), MMP-9 antibody (red), astrocyte
marker anitbody (S-100, blue), microglia marker antibody (IB4-GS, green).
GL—granular layer, ML—molecular layer. Scale bar 50 µm. The experiment
was performed by dr Grzegorz Wilczynski. For further reference, see
Wilczynski et al. (2008).
Frontiers in Neuroanatomy www.frontiersin.org July 2014 | Volume 8 | Article 68 | 8
Stawarski et al. MMP-9 related dendritic spine reshaping
Jourquin et al., 2003; Konopacki et al., 2007) and pilocarpine
(Kim et al., 2009). MMP-9 immunoreactivity (IR) is increased
24 h after kainic acid (KA) administration. IR is initially observed
in neurons, and expression remains elevated for up to 7 days.
Notably, MMP-9 IR is also observed in astrocytes (Figure 3).
The increased expression and activity of MMP-9 has been shown
to also occur with pentylenetetrazol (PTZ)-induced seizures
(Michaluk et al., 2007; Rylski et al., 2009; Mizoguchi et al., 2011b).
In these models, MMP-9 has been suggested to contribute to
neuronal death (Jourquin et al., 2003; Kim et al., 2009), dendritic
spine pruning (Szklarczyk et al., 2002), and the formation of
aberrant synaptic contacts (Szklarczyk et al., 2002).
Strong evidence for a pivotal role of MMP-9 in
epileptogenesis-related plasticity was provided by Mizoguchi
and Wilczynski (Wilczynski et al., 2008; Mizoguchi et al.,
2011a). Repeated treatment with PTZ produced kindled seizure,
accompanied by enhanced MMP-9 activity and expression in the
hippocampus (Mizoguchi et al., 2011a). The sensitivity to PTZ
kindling was decreased in MMP-9 knockout mice (Wilczynski
et al., 2008; Mizoguchi et al., 2011a). These mice also exhibited
less severe seizures. In contrast, rats with constitutive neuronal
MMP-9 overexpression that received PTZ treatment were more
susceptible to seizures than wildtype animals. MMP-9 has
been suggested to facilitate the development of seizures by
affecting epilepsy-related synaptic plasticity. Seizure-induced
MMP-9 expression was previously shown to be localized to
dendrites and synapses and implicated in synaptic remodeling
and mossy fiber sprouting, pathological structural phenomena
associated with epilepsy (Szklarczyk et al., 2002; Michaluk and
Kaczmarek, 2007; Gawlak et al., 2009). Indeed, MMP-9 protein
levels and activity localized at synapses were strongly upregulated
following intraperitoneal kainate treatment (Wilczynski et al.,
2008). In the same study, unilateral kainate injections into the
amygdala were used to induce status epilepticus. Twenty-four
hours after seizure onset, spine density decreased in the DG
on the injected side compared with the contralateral side in
MMP-9 wildtype animals. In contrast, no difference in spine
density was found between the injected and contralateral sides
in MMP-9 knockout mice. Overall, status epilepticus-induced
dendritic spine loss in the ML of the DG appears to be mediated
by MMP-9 release from spines in response to seizures. In
MMP-9 knockout animals the pruning of dendritic spines is
abolished, despite the presence of stimulus. MMP-9 was also
shown to be involved in mossy fiber sprouting and aberrant
synaptogenesis in hippocampal epileptogenesis, in which neither
of these phenomena develop in the absence of the enzyme.
Interestingly, mossy fiber sprouting sites have been associated
with the regrowth of dendritic spines in this region after status
epilepticus (Isokawa, 2000).
MMP-9 activity was also considerably enhanced in other
epilepsy models that do not involve neuronal cell loss (Baracskay
et al., 2008; Gallyas et al., 2008; Sarkisova and van Luijtelaar,
2011). MMP-9 may be involved in generalized absence epilepsy,
in which increased activity was found in WAG/Rij rats (Takacs
et al., 2010). These rats spontaneously produce absence-like
seizures caused by the hypersynchronic activity of thalamo-
cortical and corticothalamic neurons and are commonly used
as an animal model of human absence epilepsy (Coenen and
Van Luijtelaar, 2003). Interestingly, the administration of doxy-
cycline, an MMP inhibitor, aggravated epileptiform activity
in WAG/Rij rats (Kovács et al., 2011). Matrix metallopro-
teinases were previously shown to act directly on NMDA and
AMPA receptors (Michaluk et al., 2009; Gorkiewicz et al.,
2010). This may, in turn, provide a sort of balanced home-
ostatic synaptic plasticity during seizures. NMDA and AMPA
receptors are involved in the genesis of absence seizures
(Coenen and Van Luijtelaar, 2003). Therefore, MMP-9 inhi-
bition may increase the net level of excitability and increase
absence-like epileptic activity in WAG/Rij rats (Takacs et al.,
2010).
Considering the extant evidence, MMP-9 might play a dual
role in epilepsy, with distinct roles in pathogenesis at various
time-points after seizures (Michaluk and Kaczmarek, 2007). Aside
from contributing to structural remodeling, MMP-9 may also be
involved in maintaining homeostatic synaptic plasticity to coun-
teract epileptic seizures. Fast activation of MMP-9 by seizures (i.e.,
within minutes) may induce spine loss (which is not observed in
MMP-9 knockout mice) that initially alters neuronal excitability
and reduces the effects of seizures. Sustained increases in MMP-9
levels (secondary to seizures, within days) may be hypothesized
to push the balance toward the regrowth of dendritic spines
and restore system balance but in effect contribute to long-
term circuitry remodeling. Such aberrant plasticity may underlie
epileptogenesis and lead to the formation of epileptic foci in the
brain (Figure 2).
CONCLUSIONS
Brain plasticity relies on modifications in synaptic connectiv-
ity that are driven by molecular changes in neurons and the
ECM. The ability to change synaptic connections comprises
alterations of dendritic spines at the morphological level. We
reviewed the role of ECM metalloproteinase activity in physi-
ological and pathological structural plasticity. We summarized
the contribution of MMP-9 in the dynamic remodeling of the
ECM via the cleavage of numerous extracellular substrates and
its role in the formation, modification, and maintenance of
dendritic spines. Importantly, MMP-9 may serve as an exam-
ple of a proteolytic modifier of the ECM, thus supporting
the concept of a tetrapartite synapse. Finally, we examined
the morphological abnormalities of dendritic protrusions that
are well known to be associated with neuropsychiatric dis-
orders, particularly those that involve cognitive deficits. We
reviewed evidence that implicates MMP-9 in aberrant synap-
tic plasticity and spine dysmorphology in neuropsychiatric
disorders.
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